ES2195925T3 - Proceso para fabricar una formulacion de liberacion retardada. - Google Patents

Proceso para fabricar una formulacion de liberacion retardada.

Info

Publication number
ES2195925T3
ES2195925T3 ES00951802T ES00951802T ES2195925T3 ES 2195925 T3 ES2195925 T3 ES 2195925T3 ES 00951802 T ES00951802 T ES 00951802T ES 00951802 T ES00951802 T ES 00951802T ES 2195925 T3 ES2195925 T3 ES 2195925T3
Authority
ES
Spain
Prior art keywords
compound
units
polymer
inclusive
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00951802T
Other languages
English (en)
Inventor
Thomas Ciaran Loughman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kinerton Ltd
Original Assignee
Kinerton Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinerton Ltd filed Critical Kinerton Ltd
Application granted granted Critical
Publication of ES2195925T3 publication Critical patent/ES2195925T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un proceso para fabricar Compuesto (I), donde el Compuesto (I) comprende el Compuesto (A), y un polímero, donde el polímero comprende unidades de lactida, unidades de glicolida y unidades de ácido tartárico, donde la relación en el polímero de las unidades de lactida es desde 71% a 73% inclusive; de las unidades de glicolida es desde 26% a 28% inclu sive; y de las unidades de ácido tartárico es desde 1% a 3% inclusive; y donde el grupo amino del Compuesto (A) está unido iónicamente a un grupo carboxílico de las unidades de ácido del polímero; comprendiendo dicho proceso la etapa de hacer reaccionar una solución acuosa de Compuesto (A) con el polímero o una sal del mismo, en una mezcla de acetonitrilo y agua donde la relación de pesos entre el acetonitrilo y el agua es de aproximadamente 3 a 1, respectivamente, a una temperatura de aproximadamente 0ºC a 5ºC hasta que se complete sustan cialmente la formación del Compuesto (I).
ES00951802T 1999-08-18 2000-08-14 Proceso para fabricar una formulacion de liberacion retardada. Expired - Lifetime ES2195925T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE19990700A IES990700A2 (en) 1999-08-18 1999-08-18 Process to make a sustained release formulation

Publications (1)

Publication Number Publication Date
ES2195925T3 true ES2195925T3 (es) 2003-12-16

Family

ID=11042112

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00951802T Expired - Lifetime ES2195925T3 (es) 1999-08-18 2000-08-14 Proceso para fabricar una formulacion de liberacion retardada.

Country Status (25)

Country Link
US (1) US6893645B1 (es)
EP (1) EP1212095B1 (es)
JP (1) JP3730917B2 (es)
CN (2) CN1823736A (es)
AR (1) AR022647A1 (es)
AT (1) ATE243044T1 (es)
AU (1) AU755229B2 (es)
BR (1) BR0013349A (es)
CA (1) CA2380902C (es)
CZ (1) CZ294433B6 (es)
DE (1) DE60003438T2 (es)
DK (1) DK1212095T3 (es)
ES (1) ES2195925T3 (es)
HU (1) HUP0202895A3 (es)
IE (1) IES990700A2 (es)
IL (1) IL148044A0 (es)
MX (1) MXPA02001415A (es)
NO (1) NO20020762L (es)
NZ (1) NZ517251A (es)
PL (1) PL199862B1 (es)
PT (1) PT1212095E (es)
RU (1) RU2211694C1 (es)
TW (1) TWI230069B (es)
WO (1) WO2001012232A2 (es)
ZA (1) ZA200202027B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767837B2 (en) * 1999-08-18 2003-11-27 Ipsen Pharma S.A.S. Sustained release formulation of a peptide
EP1348444B1 (en) * 1999-08-18 2006-04-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Sustained release formulation of a peptide complexed with a polymer
US7109166B1 (en) 1999-08-18 2006-09-19 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Sustained release formulation of a peptide
EP1697035B1 (en) * 2003-12-22 2017-11-15 Warren H. Finlay Powder formation by atmospheric spray-freeze drying
MX2007004676A (es) 2004-10-27 2007-11-14 Univ Denver Analogos de la hormona adrenocorticotropica y metodos relacionados.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5213810A (en) * 1990-03-30 1993-05-25 American Cyanamid Company Stable compositions for parenteral administration and method of making same
DK0678018T3 (da) 1993-01-06 2003-04-28 Kinerton Ltd Ion molekylærkonjugater af bionedbrydelige polyestere og bioaktive polypeptider
US6221958B1 (en) * 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5863985A (en) * 1995-06-29 1999-01-26 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
RO117259B1 (ro) * 1993-08-09 2001-12-28 Biomeasure Inc. Derivaţi peptidici, terapeutici
IE960308A1 (en) * 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
WO1998008528A1 (en) * 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
US5972893A (en) * 1997-05-06 1999-10-26 Cedars-Sinai Medical Center Method of treating hyperprolactinemia and prolactinomas
DE69907870T2 (de) 1998-01-29 2004-03-04 Kinerton Ltd., Blanchardstown Verfahren zur herstellung von absorbierbaren mikropartikeln
CN1278195A (zh) 1998-08-28 2000-12-27 三丰株式会社 被测定工件的自动清洗装置及设有该装置的自动生产系统
AU767837B2 (en) * 1999-08-18 2003-11-27 Ipsen Pharma S.A.S. Sustained release formulation of a peptide

Also Published As

Publication number Publication date
ZA200202027B (en) 2002-12-24
WO2001012232A3 (en) 2002-04-04
DK1212095T3 (da) 2003-10-06
WO2001012232A2 (en) 2001-02-22
EP1212095B1 (en) 2003-06-18
CA2380902C (en) 2008-08-05
IL148044A0 (en) 2002-09-12
BR0013349A (pt) 2002-04-23
CN1246040C (zh) 2006-03-22
AR022647A1 (es) 2002-09-04
WO2001012232A8 (en) 2002-06-06
HK1044285A1 (en) 2002-10-18
PL354263A1 (en) 2003-12-29
NO20020762L (no) 2002-04-16
EP1212095A2 (en) 2002-06-12
PT1212095E (pt) 2003-10-31
NZ517251A (en) 2003-08-29
US6893645B1 (en) 2005-05-17
AU6464700A (en) 2001-03-13
ATE243044T1 (de) 2003-07-15
CA2380902A1 (en) 2001-02-22
AU755229B2 (en) 2002-12-05
HUP0202895A2 (hu) 2003-02-28
CZ2002266A3 (cs) 2002-05-15
JP2003507346A (ja) 2003-02-25
MXPA02001415A (es) 2002-08-12
RU2211694C1 (ru) 2003-09-10
RU2002106809A (ru) 2004-01-20
DE60003438D1 (de) 2003-07-24
HUP0202895A3 (en) 2003-11-28
CZ294433B6 (cs) 2005-01-12
DE60003438T2 (de) 2004-05-06
PL199862B1 (pl) 2008-11-28
TWI230069B (en) 2005-04-01
JP3730917B2 (ja) 2006-01-05
CN1823736A (zh) 2006-08-30
CN1377283A (zh) 2002-10-30
IES990700A2 (en) 2001-08-22
NO20020762D0 (no) 2002-02-15

Similar Documents

Publication Publication Date Title
EA200300211A1 (ru) Азабициклические соединения, способ их получения и их применение в качестве лекарственных средств, в частности в качестве антибактериальных средств
HK1049165A1 (zh) 循环β-氨基酸衍生物作为质基金属蛋白酶及TNF-α的抑制剂
AR051778A2 (es) Derivados del acido dimetilaminocrotonico y procesos para supreparacion
PE20010532A1 (es) FORMAS FARMACEUTICAS DE ADMINISTRACION ORAL AL MENOS PARCIALMENTE RETARDADAS CUYA SUSTANCIA ACTIVA FARMACEUTICA TRAMADOL SE ENCUENTRA AL MENOS PARCIALMENTE EN FORMA DE COMPUESTO FORMADO IN SITU CON UNA HIDROSOLUBILIDAD Menor o igual 100MG/ML, Y PROCE
PE20081258A1 (es) ANTICUERPOS ANTI-hTNFALFA CRISTALINOS
PE20050822A1 (es) Derivados de florfenicol con mejor solubilidad en agua
EP1413303A4 (en) PROMOTERS FOR GROWTH IN PORK AND METHOD FOR PROMOTING GROWTH IN PORK
EP1006536A3 (en) Electrolytic solution for electrolytic capacitor and electrolytic capacitor using the same
MX2022008191A (es) Soluciones orales que comprenden sales de lisdexanfetamina.
AR035556A1 (es) Derivados de acido alfa-aminohidroxamico, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
ES2195925T3 (es) Proceso para fabricar una formulacion de liberacion retardada.
ES8202015A1 (es) Un procedimiento para la preparacion de derivados de penici-lina
BR9408563A (pt) Processo para a produção de formulações sólidas contendo tensoativos de óxido de amina
WO2003059323A3 (de) Stabile salze von o-acetylsalicylsäure mit basischen aminosäuren ii
EP0302967A3 (en) Quinazoline derivative, processes for its production, and cerebral dysfunction remedying agent comprising it as active ingredient
HRP20100504T1 (hr) 2-(4-cijanofenil)-6-hidroksilaminopirimidini koji inhibiraju hiv
AR029002A1 (es) Proceso para preparar compuestos de acidos quinolin-2-carboxilicos y de sus sales farmaceuticamente aceptables
BRPI0013750B8 (pt) intermediários para a produção de derivados de ácido naftiridina-3-carboxílico
ITMI20030063A1 (it) Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
ES8505993A1 (es) Un metodo para preparar un derivado de 3-indolcarboxamida
ES2170910T3 (es) Procedimiento para la preparacion de oxido de rosas.
BR9915684A (pt) Semicloridrato de ácido 8-cian-1-ciclopropil-7-(1s,6s-2,8-diazabiciclo-[4.3.0]-non an-8-il)-6-flúor-1,4-dihidro-4-oxo-3-quinolinocarboxìli co
ES8603828A1 (es) Procedimiento de preparacion de nuevos derivados a-etilben- zol con un grupo piperidinopropanolico sustituido y de sus sales de adicion acidas y amonicas cuaternarias
AR044230A1 (es) Composicion agroquimica en suspension acuosa
BRPI0407073A (pt) ésteres de ácido carboxìlico de compostos farmacêuticos